Research programme: superoxide dismutase variants - Apex BioscienceAlternative Names: Superoxide dismutase variants research programme - Apex Bioscience
Latest Information Update: 21 Dec 2000
At a glance
- Originator Curacyte Inc
- Mechanism of Action Free radical scavengers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation; Reperfusion injury
Most Recent Events
- 21 Dec 2000 Discontinued-Preclinical for Reperfusion injury in USA (Unknown route)
- 21 Dec 2000 Discontinued-Preclinical for Inflammation in USA (Unknown route)
- 21 Dec 2000 Discontinued-Preclinical for Autoimmune disorders in USA (Unknown route)